R
Roham T. Zamanian
Researcher at Stanford University
Publications - 163
Citations - 5669
Roham T. Zamanian is an academic researcher from Stanford University. The author has contributed to research in topics: Pulmonary hypertension & Medicine. The author has an hindex of 37, co-authored 147 publications receiving 4283 citations. Previous affiliations of Roham T. Zamanian include University of California, Irvine & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL: Identifying Systemic Sclerosis as a Unique Phenotype
Lorinda Chung,Lorinda Chung,Juliana Liu,Lori Parsons,Paul M. Hassoun,Michael D. McGoon,David B. Badesch,Dave P. Miller,Mark R. Nicolls,Mark R. Nicolls,Roham T. Zamanian +10 more
TL;DR: In this article, the authors used the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) to analyze the clinical features of patients with connective tissue disease-associated PAH (CTD-APAH).
Journal ArticleDOI
Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
Bradley A. Maron,Bradley A. Maron,Edward Hess,Thomas M. Maddox,Thomas M. Maddox,Alexander R. Opotowsky,Ryan J. Tedford,Tim Lahm,Karen E. Joynt,Daniel J. Kass,Thomas Stephens,Maggie A. Stanislawski,Erik R. Swenson,Ronald H. Goldstein,Jane A. Leopold,Roham T. Zamanian,Jean M. Elwing,Mary E. Plomondon,Gary K. Grunwald,Anna E. Barón,John S. Rumsfeld,Gaurav Choudhary +21 more
TL;DR: In this paper, the Cox proportional hazards models were used to evaluate the association between pulmonary artery pressure (mPAP) and outcomes of all-cause mortality and hospitalization, adjusted for clinical covariates.
Journal ArticleDOI
Insulin resistance in pulmonary arterial hypertension
Roham T. Zamanian,Georg Hansmann,Shannon Snook,David Lilienfeld,Karen M Rappaport,Gerald M. Reaven,Marlene Rabinovitch,Ramona L. Doyle +7 more
TL;DR: The presence of IR and a higher NYHA class was associated with poorer 6-months event-free survival and insulin resistance appears to be a novel risk factor or disease modifier that might impact on survival.
Journal ArticleDOI
Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension.
Wen Tian,Xinguo Jiang,Rasa Tamosiuniene,Yon K. Sung,Jin Qian,Gundeep Dhillon,Lajos Gera,Laszlo Farkas,Marlene Rabinovitch,Roham T. Zamanian,Mohammed Inayathullah,Marina Fridlib,Jayakumar Rajadas,Marc Peters-Golden,Norbert F. Voelkel,Mark R. Nicolls +15 more
TL;DR: The authors found that damping down excess LTB4 by inhibiting its biosynthesis could reverse disease: in treated animals, cardiac function improved and obstructed arterioles opened, and the authors uncovered a possible role for macrophage-derived LTB 4 in PH pathogenesis and identify a pathway that may be amenable to therapeutic targeting.
Journal ArticleDOI
Management strategies for patients with pulmonary hypertension in the intensive care unit
TL;DR: Treatment of pulmonary hypertension resulting from critical illness or chronic lung diseases should address the primary cause of hemodynamic deterioration, and pulmonary vasodilators usually are not necessary.